- Home
- PRLD vs TEI Comparison
PRLD vs TEI Comparison
Compare PRLD & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRLD | TEI |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.2M | 300.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRLD | TEI |
|---|---|---|
| Price | $3.95 | $6.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.67 | N/A |
| AVG Volume (30 Days) | ★ 298.3K | 156.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.51% |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,140,000.00 | N/A |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.75 | $5.72 |
| 52 Week High | $5.54 | $7.00 |
Technical Indicators
Market Signals| Indicator | PRLD | TEI |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 49.44 |
| Support Level | $3.92 | $6.24 |
| Resistance Level | $4.10 | $6.48 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 59.44 | 56.34 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.